

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Mark E. Samuels et al.
Serial No. : 10/552,158 Art Unit: 1656
Filed : 11 December 2006 Examiner: Monshipouri, M.
For : Juvenile Hemochromatosis Gene (HFE2A), Expression
Products and Uses Thereof
Docket No. : 760050-154

4 September 2009

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

☒ [X] Copies of cited references are enclosed herewith

☐ [] Copies of cited references have been submitted in parent application

Serial No. _____ (37 C.F.R. 1.98(d))

The Information Disclosure Statement submitted herewith is being filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

The Information Disclosure Statement is being filed:

- ☒ **Within three months of the filing date of a national application;**
OR
Within three months of the date of entry of the national stage of
an international application; OR
Before the mailing of a first Office Action on the merits.
(37 C.F.R. 1.97(b)).

OR ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114 (37 C.F.R. 1.97(b)(4)).

No fee or statement is required.

The Information Disclosure Statement is being filed after the period specified in 37 C.F.R. 1.97(b) above (37 C.F.R. 1.97(c), but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
(2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- ☐ The statement as specified in 37 CFR §1.97(e) set out below; OR
☐ The fee of \$180.00 under 37 CFR §1.17(p).

The Information Disclosure Statement is being filed:

- ☐ after the mailing date of a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311 but before payment of the Issue Fee and is accompanied by:
- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

Serial No.: 10/552,158
Docket No. 760050-154

In accordance with 37 C.F.R. 1.97(d), the undersigned Agent/Attorney hereby states that:

☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

OR

☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

☐ Payment is enclosed.


☒ Please charge any required fees to Deposit Account No. 03-0678.

☐ A duplicate copy of this paper is attached.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

E-filed 9/4/09

Respectfully submitted,



Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
5 Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744